Can you get medical cannabis for Crohn's disease?
Crohn's is the condition where the gap between feeling better and being better is at its most consequential. Inflammation that is not controlled causes damage whether or not the symptoms have quietened down.
The short answer
- The Cochrane review found no evidence that cannabis induces clinical remission in Crohn's disease.
- Small trials report symptom improvement without a corresponding fall in inflammatory markers.
- That distinction matters more here than elsewhere. Uncontrolled inflammation causes structural damage.
- Established therapies come first, and stopping them is not something to do unilaterally.
- It never replaces gastroenterology follow-up, including monitoring and endoscopy.
Is Crohn's disease assessed for medical cannabis?
Yes, privately, and usually for symptom burden rather than for the disease itself. No cannabis-based product is licensed for Crohn's disease, and NICE guidance on its management does not include them.
This page covers Crohn's specifically. The broader picture, including ulcerative colitis, is in medical cannabis for inflammatory bowel disease, and the distinct question of IBS is in medical cannabis for irritable bowel syndrome.
What the evidence actually shows
The Cochrane review is the reference point, and its conclusion was negative for remission. The individual trials it examined were small, short, and reported improvement in how people felt rather than in measured inflammation.
The review behind that paragraph
Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the treatment of Crohn's disease. Cochrane Database of Systematic Reviews, 2018. The authors found no firm conclusions could be drawn about the effectiveness and safety of cannabis in Crohn's disease, and that the included studies were small with low-quality evidence.
The most-cited individual study randomised a small number of patients with active Crohn's to smoked cannabis or placebo and reported improvement in symptom scores. Inflammatory markers did not change correspondingly. That pattern — symptoms better, inflammation unchanged — has repeated across the small studies since.
A reasonable reading is that cannabis-based medicines may help some people feel better without treating the disease process. That is not worthless, and it is not remission.
Why that distinction matters so much in Crohn's
Because Crohn's causes cumulative structural damage — strictures, fistulas and the operations that follow — and that damage tracks inflammation rather than symptoms.
Someone whose symptoms are masked while inflammation continues can feel reasonably well while the disease progresses. This is the specific risk a gastroenterologist is thinking about, and it is why symptom improvement alone does not reassure them.
It is also why any use alongside Crohn's treatment belongs inside gastroenterology follow-up, with the monitoring that normally involves, rather than as a private arrangement your IBD team does not know about.
What a specialist will want to see
The disease-modifying treatments you have had, what happened with each, and what your current disease activity actually is on objective measures rather than on how you feel.
- Your diagnosis, disease location and behaviour, and how long you have had it
- Which therapies you have tried, and whether each failed, was not tolerated, or was stopped for another reason
- Recent inflammatory markers, faecal calprotectin, imaging or endoscopy
- Previous surgery, strictures or fistulas
- Whether your IBD team knows you are considering this
- Smoking, which independently worsens Crohn's disease
That last point is worth stating plainly: smoking is one of the clearest modifiable risk factors in Crohn's, and inhaling any smoked material sits badly with that. See vaporising versus smoking.
The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?
Risks and reasons a specialist may say no
The general cautions apply, and two specific ones carry extra weight in inflammatory bowel disease.
The first is masking. A treatment that improves symptoms without improving inflammation can delay a change of therapy that was needed. The second is displacement: people occasionally reduce or stop an immunosuppressant or biologic because they feel better, which is the sequence that leads to hospital admissions.
Stopping or reducing Crohn's therapy is a decision for the team that prescribed it, and nothing on this page is a reason to do it.
If you want to take this further
The useful next step is a proper assessment, not a longer reading list. Gather your diagnosis, the treatments you have already tried and what happened with each, and a current list of your medicines — that is what a specialist needs in order to give you a straight answer.
The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If Crohn's disease is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.
Frequently asked questions
Does medical cannabis treat Crohn's disease?
The Cochrane review found no firm evidence that cannabis induces clinical remission in Crohn's disease. Small trials report improvement in symptoms without a corresponding change in inflammatory markers, which suggests it may help some people feel better without treating the disease process.
Can I get medical cannabis for Crohn's in the UK?
You can be assessed for it privately. No cannabis-based product is licensed for Crohn's disease, and a specialist will expect established therapies to have been tried and will want objective measures of your current disease activity.
Can I stop my biologic or immunosuppressant if it helps?
No. That decision belongs to the team that prescribed it. Symptom improvement without reduced inflammation is exactly the situation in which stopping disease-modifying treatment causes harm.
Is this different from ulcerative colitis?
The evidence pattern is similar but the conditions are not the same, and the trials are separate. Ulcerative colitis is covered in the inflammatory bowel disease guide.
Sources and further reading
Every factual statement on this page is drawn from the following public sources. Links open in a new tab and are not affiliated with Flora House.
- Kafil TS, et al. Cannabis for the treatment of Crohn's disease. Cochrane Database of Systematic Reviews (2018)
- NICE guideline NG129: Crohn's disease — management
- NHS: Crohn's disease
- NICE guideline NG144: Cannabis-based medicinal products
- NHS: Medical cannabis (and cannabis oils)
- MHRA: The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use